Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide
- PMID: 18540827
- DOI: 10.1615/critrevimmunol.v28.i2.20
Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide
Abstract
Cyclophosphamide (CTX) is an alkylating cytotoxic drug that primarily affects proliferating lymphocytes. CTX has been extensively used as a chemotherapeutic and disease-modifying agent against certain solid tumors, lymphomas, and some autoimmune conditions. Depending on its dose and timing of administration, CTX can also enhance immune responses. These opposing immune functions of CTX have been investigated in numerous animal models and recent clinical studies. Administration of CTX augments delayed type 1 hypersensitivity (DTH) reactions, can precipitate type 1 diabetes, and boosts antitumor responses in both vaccination and adoptive cell transfer models. Although the mechanisms by which CTX elicits these effects are not fully understood, CTX treatment has a differential effect on lymphocyte compartments, rapidly depleting B and T cells. This is followed by a recovery phase characterized by extensive proliferation and bone marrow mobilization. The proposed underlying mechanisms of augmentation of immune responses include the facilitation of homing and homeostatic proliferation by the creation of space, the skewing of Th2/Th1 responses due to the cytokine storm during the recovery phase, and the removal or inhibition of a suppressor cell population. With the identification of naturally occurring and peripheral regulatory T cells, recent studies have re-evaluated these hypotheses and suggest that CTX inhibits the function of Foxp3+ regulatory T cells. In this review, we critically evaluate relevant historical and recent data on CTX-mediated immunomodulation and discuss the resulting implications for immunotherapy.
Similar articles
-
Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.J Clin Invest. 1998 Jan 15;101(2):429-41. doi: 10.1172/JCI1348. J Clin Invest. 1998. PMID: 9435316 Free PMC article.
-
Ifosfamide and cyclophosphamide: effects on immunosurveillance.Oncology. 2003;65 Suppl 2:17-20. doi: 10.1159/000073353. Oncology. 2003. PMID: 14586142 Review.
-
Role of interferon regulatory factor 1 in governing Treg depletion, Th1 polarization, inflammasome activation and antitumor efficacy of cyclophosphamide.Int J Cancer. 2018 Mar 1;142(5):976-987. doi: 10.1002/ijc.31083. Epub 2017 Oct 16. Int J Cancer. 2018. PMID: 28975621
-
Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide.Cancer Res. 2011 May 15;71(10):3528-39. doi: 10.1158/0008-5472.CAN-10-4523. Epub 2011 Mar 28. Cancer Res. 2011. PMID: 21444678
-
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.Semin Immunopathol. 2011 Jul;33(4):369-83. doi: 10.1007/s00281-011-0245-0. Epub 2011 May 25. Semin Immunopathol. 2011. PMID: 21611872 Review.
Cited by
-
Modulation of Immune Cell Functions by the E3 Ligase Cbl-b.Front Oncol. 2015 Mar 11;5:58. doi: 10.3389/fonc.2015.00058. eCollection 2015. Front Oncol. 2015. PMID: 25815272 Free PMC article. Review.
-
The future of cancer immunotherapy: microenvironment-targeting combinations.Cell Res. 2020 Jun;30(6):507-519. doi: 10.1038/s41422-020-0337-2. Epub 2020 May 28. Cell Res. 2020. PMID: 32467593 Free PMC article.
-
Transcriptional characterization of immunological infiltrates and their relation with glioblastoma patients overall survival.Oncoimmunology. 2018 Feb 12;7(6):e1431083. doi: 10.1080/2162402X.2018.1431083. eCollection 2018. Oncoimmunology. 2018. PMID: 29872555 Free PMC article.
-
Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach.Biomedicines. 2024 Jan 18;12(1):217. doi: 10.3390/biomedicines12010217. Biomedicines. 2024. PMID: 38255322 Free PMC article. Review.
-
Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.Semin Immunol. 2010 Jun;22(3):162-72. doi: 10.1016/j.smim.2010.02.003. Epub 2010 May 26. Semin Immunol. 2010. PMID: 20537908 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources